Monopolar stereoelectroencephalography-guided radiofrequency thermocoagulation
Journal of Neurosurgery · 2024
DOI: 10.3171/2023.7.jns23319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurosurgery, 2024. Verfasst von Krasimir T Minkin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of1Neurosurgery and. Hauptthemen laut MEDLINE: Epilepsy, Drug Resistant Epilepsy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE Stereoelectroencephalography (SEEG)–guided radiofrequency thermocoagulation (RFTC) has the advantage of producing a lesion in the epileptogenic zone (EZ) at the end of SEEG. The majority of published SEEG-guided RFTCs have been bipolar and usually performed between contiguous contacts of the same electrode. In the present study, the authors evaluate the safety, efficacy, and benefits of monopolar RFTC at the end of SEEG. METHODS This study included a series of 31 consecutive patients who had undergone RFTC at the end of SEEG for drug-resistant focal epilepsy in the period of January 2013–December 2019. Post-RFTC seizure control was assessed after 2 months and at the last follow-up visit. Twenty-one patients underwent resective epilepsy surgery after the SEEG-guided RFTC, and the postoperative seizure outcome among these patients was compared with the post-RFTC seizure outcome. RESULTS Four hundred forty-six monopolar RFTCs were done in the 31 patients. Monopolar RFTCs were performed in all cortical areas, including the insular cortex in 11 patients (56 insular RFTCs). There were 31 noncontiguous lesions (7.0%) because of vascular constraints. The volume of one monopolar RFTC, as measured on T2-weighted MRI immediately after the procedure, was between 44 and 56 mm 3 (mean 50 mm 3 ). The 2-month post-RFTC seizure outcomes were as follows: seizure freedom in 13 patients (41.9%), ≥ 50% reduced seizure frequency in 11 (35.5%), and no significant change in 7 (22.6%). Seizure outcome at the last follow-up visit (mean 18 months, range 2–54 months) showed seizure freedom in 2 patients (6.5%) and ≥ 50% reduced seizure frequency in 20 patients (64.5%). Seizure freedom after monopolar RFTC was not significantly associated with the number or location of coagulated contacts. Seizure response after monopolar RFTC had a high positive predictive value (93.8%) but a low negative predictive value (40%) for seizure outcome after subsequent resective surgery. In this series, the only complication (3.2%) was a limited intraventricular hematoma following RFTC performed in the hippocampal head, with spontaneous resolution and no sequelae. CONCLUSIONS The use of monopolar SEEG-guided RFTC provides more freedom in terms of choosing the SEEG contacts for thermocoagulation and a larger thermolesion volume. Monopolar thermocoagulation seems particularly beneficial in cases with an insular EZ, in which vascular constraints could be partially avoided by making noncontiguous lesions within the EZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of1Neurosurgery and.
- 2Interventional Radiology, University Hospital "Sveti Ivan Rilski," Sofia, Bulgaria.
Zitieren
APA
Minkin, K. T., Gabrovski, K. R., Milenova, Y. T., Karazapryanov, P. A., Sirakov, S. S., & Dimova, P. S. (2024). Monopolar stereoelectroencephalography-guided radiofrequency thermocoagulation. Journal of Neurosurgery. https://doi.org/10.3171/2023.7.jns23319
Vancouver
Minkin KT, Gabrovski KR, Milenova YT, Karazapryanov PA, Sirakov SS, Dimova PS. Monopolar stereoelectroencephalography-guided radiofrequency thermocoagulation. Journal of Neurosurgery. 2024. doi:10.3171/2023.7.jns23319
BibTeX
@article{Minkin2024,
author = {Minkin, Krasimir T and Gabrovski, Kaloyan R and Milenova, Yoana T and Karazapryanov, Petar A and Sirakov, Stanimir S and Dimova, Petia S},
title = {Monopolar stereoelectroencephalography-guided radiofrequency thermocoagulation},
journal = {Journal of Neurosurgery},
year = {2024},
doi = {10.3171/2023.7.jns23319}
}
EUVIMED